The study, published in Lancet Neurology, detailed the "head-to-head" trial implemented by the researchers to test two drugs, mexiletine and lamotrigine, on people with the condition.

Researchers at Fred Hutch Cancer Center identified a substantial increase over the past decade in the proportion of patients with cancer in the U.S. who participate in pharmaceutical industry sponsored clinical trials compared to those conducted with federal government support.

A study led by Brazilian researchers and reported in an article published in the journal Nature Communications proposes that simultaneously targeting the enzyme glutaminase and the protein HuR, both of which are essential to tumor progression, may be effective in treating breast cancer.

Researchers with McMaster University have discovered that the protein mutated in patients with Huntington's Disease doesn't repair DNA as intended, impacting the ability of brain cells to heal themselves.

Estrogens are known to drive tumor growth in breast cancer cells that carry its receptors, but a new study by Duke Cancer Institute researchers unexpectedly finds that estrogens play a role in fueling the growth of breast cancers without the receptors, as well as numerous other cancers.

Research from the University of California, Irvine has revealed how disruption of the circadian clock, the body's internal, 24-hour biological pacemaker, may accelerate the progression of colorectal cancer by affecting the gut microbiome and intestinal barrier function.